Akrivis Technologies, LLC is a privately held biopharmaceutical company committed to the early detection, diagnosis and treatment of serious and life-threatening diseases based on its patented Z-TECT™ technology platform.

Akrivis’ main asset is its proprietary Z–TECT™ Technology Platform, which has been shown to provide high sensitivity detection and accurate quantification of biomolecules down to the zeptomole range (10E–21 moles), therefore potentially allowing the detection of less than a thousand individual molecules.  In addition to supporting in vitro and in vivo diagnostics, Z–TECT™ can also serve as a novel platform for the targeted delivery of a high payload of radio- or chemo-therapeutic drugs for cancer treatment.  Potentially enabling far safer and more efficacious targeted delivery therapies, Z–TECT™ could also have a major impact on the emerging field of “Theranostics”, which simultaneously combines diagnostics and therapy.